INOVIO PHARMACEUTICALS, INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
INOVIO PHARMACEUTICALS, INC. (INO) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2022-03-01
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2020-03-31 was $0.00.
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2019-12-31 was $69.01K.
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2019-09-30 was $0.00.
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2019-06-30 was -$117.41K.
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2021 was $0.00.
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2020 was $0.00.
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2019 was -$266.21K.
- INOVIO PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2018 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | $69.01K derived: sum of 2 quarters · filed 2022-03-01 | $69.01K derived: sum of 3 quarters · filed 2022-03-01 | -$48.40K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $69.01K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $69.01K derived: sum of 2 quarters · filed 2022-03-01 | -$48.40K derived: sum of 3 quarters · filed 2022-03-01 | -$266.21K 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$117.41K derived: sum of 2 quarters · filed 2019-11-12 | -$335.23K 10-Q · filed 2019-11-12 | -$335.23K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$117.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$335.23K 10-Q · filed 2019-08-08 | -$335.23K derived: sum of 3 quarters · filed 2021-03-01 | -$335.23K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$217.82K 10-Q · filed 2020-05-11 | -$217.82K derived: sum of 2 quarters · filed 2021-03-01 | -$217.82K derived: sum of 3 quarters · filed 2021-03-01 | -$217.82K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-12 | |||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 | |||
| 2015-09-30 | -$1.79M 10-Q · filed 2016-11-09 | |||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |